Naviscan Announces Partnership With Tecnologie Avanzate for Italian Market

PEM Now Available as Tool to Help Italian Women in the Fight against Breast Cancer

SAN DIEGO, May 3, 2011 - Naviscan, Inc., the leader in 3D Molecular Breast Imaging (MBI), has
entered into a distribution agreement with Tecnologie Avanzate s.r.l. to
market and service Naviscan's high-resolution organ-specific PET scanner in
Italy. The agreement represents the introduction of PEM (Positron Emission
Mammography), the scanner's breast application, as a new tool available to
Italian women in their fight against breast cancer.

Naviscan manufactures the only commercially-available PEM scanner and
PEM-guided biopsy system. The scanner uses PET technology to produce
tomographic images that allow physicians to visualize breast tumors down to 2
mm, the width of a grain of rice. In recently published data, PEM has been
found to be significantly more precise at identifying benign and cancerous
lesions, in what scientists call "specificity", therefore reducing the number
of unnecessary biopsies. This finding is a welcomed outcome for women and
physicians looking for ways to reduce the patient trauma and cost associated
with unnecessary procedures.

Tecnologie Avanzate and its partners have specialized in high tech
medical equipment in the fields of nuclear imaging, radiation therapy and
breast imaging since 1959 and is the exclusive distributor for Hologic(R) and
TomoTherapy(R) products. The Naviscan PET scanner is an ideal complement to
Tecnologie Avanzate's breast and nuclear imaging expertise and an ideal
partner to continue its expansion in Europe.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution
PET scanners intended to provide organ-specific molecular imaging and guide
radiological and surgical procedures. The Naviscan PET scanner is currently
installed and available in breast and imaging centers throughout the U.S. and
other parts of the world. The Company is headquartered in San Diego,
California and is the first to obtain FDA-clearance for a high-resolution PET
scanner designed to image small body parts and for breast biopsy image
guidance. For more information, call +1-858-587-3641 or visit
www.naviscan.com

Guillaume Bailliard, Executive Vice President of Naviscan, Inc., +1-858-332-0941, gbailliard at naviscan.com; or Guido Catolla, CEO, Tecnologie Avanzate s.r.l., +39-(011)-66-00-101, guido.catolla at tecnologieavanzate.com